0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neurodegenerative Disorder Therapeutics Market Research Report 2024
Published Date: February 2024
|
Report Code: QYRE-Auto-2I13677
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Neurodegenerative Disorder Therapeutics Market Research Report 2023
BUY CHAPTERS

Global Neurodegenerative Disorder Therapeutics Market Research Report 2024

Code: QYRE-Auto-2I13677
Report
February 2024
Pages:95
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Neurodegenerative Disorder Therapeutics Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Neurodegenerative Disorder Therapeutics Market

Neurodegenerative Disorder Therapeutics Market

The goal of therapeutic development for neurodegenerative disorders is to develop drugs that slow down or stop the neurodegenerative process. So-called neuroprotective, or disease-modifying, therapies would not only treat the symptoms but slow the continued loss of neurons in disease.
The global Neurodegenerative Disorder Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Disorder Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Disorder Therapeutics.

Report Scope

The Neurodegenerative Disorder Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurodegenerative Disorder Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Disorder Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Neurodegenerative Disorder Therapeutics Market Report

Report Metric Details
Report Name Neurodegenerative Disorder Therapeutics Market
CAGR 5%
Segment by Type
  • Immunomodulators
  • Interferons
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Others
Segment by Application
  • Multiple Sclerosis
  • Parkinson'S Disease
  • Alzheimer'S Disease
  • Spinal Muscular Atrophy
  • Huntington Disease
  • Other Neurodegenerative Disorders
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Biogen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann- La Roche Ltd., H. Lundbeck, Merck KGaA, GlaxoSmithKline PLC, AbbVie Inc., Bristol Myers Squibb Company, Boehringer Ingeiheim International GmbH, Bayer AG, Eisai Co., Ltd
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Neurodegenerative Disorder Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Neurodegenerative Disorder Therapeutics Market report?

Ans: The main players in the Neurodegenerative Disorder Therapeutics Market are Biogen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann- La Roche Ltd., H. Lundbeck, Merck KGaA, GlaxoSmithKline PLC, AbbVie Inc., Bristol Myers Squibb Company, Boehringer Ingeiheim International GmbH, Bayer AG, Eisai Co., Ltd

What are the Application segmentation covered in the Neurodegenerative Disorder Therapeutics Market report?

Ans: The Applications covered in the Neurodegenerative Disorder Therapeutics Market report are Multiple Sclerosis, Parkinson'S Disease, Alzheimer'S Disease, Spinal Muscular Atrophy, Huntington Disease, Other Neurodegenerative Disorders

What are the Type segmentation covered in the Neurodegenerative Disorder Therapeutics Market report?

Ans: The Types covered in the Neurodegenerative Disorder Therapeutics Market report are Immunomodulators, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Immunomodulators
1.2.3 Interferons
1.2.4 Decarboxylase Inhibitors
1.2.5 Dopamine Agonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Disorder Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Multiple Sclerosis
1.3.3 Parkinson'S Disease
1.3.4 Alzheimer'S Disease
1.3.5 Spinal Muscular Atrophy
1.3.6 Huntington Disease
1.3.7 Other Neurodegenerative Disorders
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Disorder Therapeutics Market Perspective (2019-2030)
2.2 Neurodegenerative Disorder Therapeutics Growth Trends by Region
2.2.1 Global Neurodegenerative Disorder Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neurodegenerative Disorder Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Neurodegenerative Disorder Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Neurodegenerative Disorder Therapeutics Market Dynamics
2.3.1 Neurodegenerative Disorder Therapeutics Industry Trends
2.3.2 Neurodegenerative Disorder Therapeutics Market Drivers
2.3.3 Neurodegenerative Disorder Therapeutics Market Challenges
2.3.4 Neurodegenerative Disorder Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Disorder Therapeutics Players by Revenue
3.1.1 Global Top Neurodegenerative Disorder Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Disorder Therapeutics Revenue
3.4 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio
3.4.1 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disorder Therapeutics Revenue in 2023
3.5 Neurodegenerative Disorder Therapeutics Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Disorder Therapeutics Product Solution and Service
3.7 Date of Enter into Neurodegenerative Disorder Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Disorder Therapeutics Breakdown Data by Type
4.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2025-2030)
5 Neurodegenerative Disorder Therapeutics Breakdown Data by Application
5.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neurodegenerative Disorder Therapeutics Market Size (2019-2030)
6.2 North America Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024)
6.4 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurodegenerative Disorder Therapeutics Market Size (2019-2030)
7.2 Europe Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024)
7.4 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurodegenerative Disorder Therapeutics Market Size (2019-2030)
9.2 Latin America Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen, Inc.
11.1.1 Biogen, Inc. Company Detail
11.1.2 Biogen, Inc. Business Overview
11.1.3 Biogen, Inc. Neurodegenerative Disorder Therapeutics Introduction
11.1.4 Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.1.5 Biogen, Inc. Recent Development
11.2 Pfizer, Inc.
11.2.1 Pfizer, Inc. Company Detail
11.2.2 Pfizer, Inc. Business Overview
11.2.3 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Introduction
11.2.4 Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.2.5 Pfizer, Inc. Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Detail
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Neurodegenerative Disorder Therapeutics Introduction
11.3.4 Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.3.5 Novartis AG Recent Development
11.4 Sanofi S.A.
11.4.1 Sanofi S.A. Company Detail
11.4.2 Sanofi S.A. Business Overview
11.4.3 Sanofi S.A. Neurodegenerative Disorder Therapeutics Introduction
11.4.4 Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.4.5 Sanofi S.A. Recent Development
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Introduction
11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.5.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.6 UCB S.A.
11.6.1 UCB S.A. Company Detail
11.6.2 UCB S.A. Business Overview
11.6.3 UCB S.A. Neurodegenerative Disorder Therapeutics Introduction
11.6.4 UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.6.5 UCB S.A. Recent Development
11.7 F. Hoffmann- La Roche Ltd.
11.7.1 F. Hoffmann- La Roche Ltd. Company Detail
11.7.2 F. Hoffmann- La Roche Ltd. Business Overview
11.7.3 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Introduction
11.7.4 F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.7.5 F. Hoffmann- La Roche Ltd. Recent Development
11.8 H. Lundbeck
11.8.1 H. Lundbeck Company Detail
11.8.2 H. Lundbeck Business Overview
11.8.3 H. Lundbeck Neurodegenerative Disorder Therapeutics Introduction
11.8.4 H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.8.5 H. Lundbeck Recent Development
11.9 Merck KGaA
11.9.1 Merck KGaA Company Detail
11.9.2 Merck KGaA Business Overview
11.9.3 Merck KGaA Neurodegenerative Disorder Therapeutics Introduction
11.9.4 Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.9.5 Merck KGaA Recent Development
11.10 GlaxoSmithKline PLC
11.10.1 GlaxoSmithKline PLC Company Detail
11.10.2 GlaxoSmithKline PLC Business Overview
11.10.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Introduction
11.10.4 GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.10.5 GlaxoSmithKline PLC Recent Development
11.11 AbbVie Inc.
11.11.1 AbbVie Inc. Company Detail
11.11.2 AbbVie Inc. Business Overview
11.11.3 AbbVie Inc. Neurodegenerative Disorder Therapeutics Introduction
11.11.4 AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.11.5 AbbVie Inc. Recent Development
11.12 Bristol Myers Squibb Company
11.12.1 Bristol Myers Squibb Company Company Detail
11.12.2 Bristol Myers Squibb Company Business Overview
11.12.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Introduction
11.12.4 Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.12.5 Bristol Myers Squibb Company Recent Development
11.13 Boehringer Ingeiheim International GmbH
11.13.1 Boehringer Ingeiheim International GmbH Company Detail
11.13.2 Boehringer Ingeiheim International GmbH Business Overview
11.13.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Introduction
11.13.4 Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.13.5 Boehringer Ingeiheim International GmbH Recent Development
11.14 Bayer AG
11.14.1 Bayer AG Company Detail
11.14.2 Bayer AG Business Overview
11.14.3 Bayer AG Neurodegenerative Disorder Therapeutics Introduction
11.14.4 Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.14.5 Bayer AG Recent Development
11.15 Eisai Co., Ltd
11.15.1 Eisai Co., Ltd Company Detail
11.15.2 Eisai Co., Ltd Business Overview
11.15.3 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Introduction
11.15.4 Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.15.5 Eisai Co., Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of Immunomodulators
    Table 3. Key Players of Interferons
    Table 4. Key Players of Decarboxylase Inhibitors
    Table 5. Key Players of Dopamine Agonists
    Table 6. Key Players of Others
    Table 7. Global Neurodegenerative Disorder Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 8. Global Neurodegenerative Disorder Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 9. Global Neurodegenerative Disorder Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 10. Global Neurodegenerative Disorder Therapeutics Market Share by Region (2019-2024)
    Table 11. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 12. Global Neurodegenerative Disorder Therapeutics Market Share by Region (2025-2030)
    Table 13. Neurodegenerative Disorder Therapeutics Market Trends
    Table 14. Neurodegenerative Disorder Therapeutics Market Drivers
    Table 15. Neurodegenerative Disorder Therapeutics Market Challenges
    Table 16. Neurodegenerative Disorder Therapeutics Market Restraints
    Table 17. Global Neurodegenerative Disorder Therapeutics Revenue by Players (2019-2024) & (US$ Million)
    Table 18. Global Neurodegenerative Disorder Therapeutics Market Share by Players (2019-2024)
    Table 19. Global Top Neurodegenerative Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2023)
    Table 20. Ranking of Global Top Neurodegenerative Disorder Therapeutics Companies by Revenue (US$ Million) in 2023
    Table 21. Global 5 Largest Players Market Share by Neurodegenerative Disorder Therapeutics Revenue (CR5 and HHI) & (2019-2024)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Neurodegenerative Disorder Therapeutics Product Solution and Service
    Table 24. Date of Enter into Neurodegenerative Disorder Therapeutics Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Neurodegenerative Disorder Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 27. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2019-2024)
    Table 28. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 29. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2025-2030)
    Table 30. Global Neurodegenerative Disorder Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 31. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Application (2019-2024)
    Table 32. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 33. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Application (2025-2030)
    Table 34. North America Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 35. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 36. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 37. Europe Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 38. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 39. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 40. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 41. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 42. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2025-2030) & (US$ Million)
    Table 43. Latin America Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 46. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 47. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 48. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 49. Biogen, Inc. Company Detail
    Table 50. Biogen, Inc. Business Overview
    Table 51. Biogen, Inc. Neurodegenerative Disorder Therapeutics Product
    Table 52. Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 53. Biogen, Inc. Recent Development
    Table 54. Pfizer, Inc. Company Detail
    Table 55. Pfizer, Inc. Business Overview
    Table 56. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product
    Table 57. Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 58. Pfizer, Inc. Recent Development
    Table 59. Novartis AG Company Detail
    Table 60. Novartis AG Business Overview
    Table 61. Novartis AG Neurodegenerative Disorder Therapeutics Product
    Table 62. Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 63. Novartis AG Recent Development
    Table 64. Sanofi S.A. Company Detail
    Table 65. Sanofi S.A. Business Overview
    Table 66. Sanofi S.A. Neurodegenerative Disorder Therapeutics Product
    Table 67. Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 68. Sanofi S.A. Recent Development
    Table 69. Teva Pharmaceutical Industries Ltd. Company Detail
    Table 70. Teva Pharmaceutical Industries Ltd. Business Overview
    Table 71. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product
    Table 72. Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 73. Teva Pharmaceutical Industries Ltd. Recent Development
    Table 74. UCB S.A. Company Detail
    Table 75. UCB S.A. Business Overview
    Table 76. UCB S.A. Neurodegenerative Disorder Therapeutics Product
    Table 77. UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 78. UCB S.A. Recent Development
    Table 79. F. Hoffmann- La Roche Ltd. Company Detail
    Table 80. F. Hoffmann- La Roche Ltd. Business Overview
    Table 81. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product
    Table 82. F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 83. F. Hoffmann- La Roche Ltd. Recent Development
    Table 84. H. Lundbeck Company Detail
    Table 85. H. Lundbeck Business Overview
    Table 86. H. Lundbeck Neurodegenerative Disorder Therapeutics Product
    Table 87. H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 88. H. Lundbeck Recent Development
    Table 89. Merck KGaA Company Detail
    Table 90. Merck KGaA Business Overview
    Table 91. Merck KGaA Neurodegenerative Disorder Therapeutics Product
    Table 92. Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 93. Merck KGaA Recent Development
    Table 94. GlaxoSmithKline PLC Company Detail
    Table 95. GlaxoSmithKline PLC Business Overview
    Table 96. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product
    Table 97. GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 98. GlaxoSmithKline PLC Recent Development
    Table 99. AbbVie Inc. Company Detail
    Table 100. AbbVie Inc. Business Overview
    Table 101. AbbVie Inc. Neurodegenerative Disorder Therapeutics Product
    Table 102. AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 103. AbbVie Inc. Recent Development
    Table 104. Bristol Myers Squibb Company Company Detail
    Table 105. Bristol Myers Squibb Company Business Overview
    Table 106. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product
    Table 107. Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 108. Bristol Myers Squibb Company Recent Development
    Table 109. Boehringer Ingeiheim International GmbH Company Detail
    Table 110. Boehringer Ingeiheim International GmbH Business Overview
    Table 111. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product
    Table 112. Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 113. Boehringer Ingeiheim International GmbH Recent Development
    Table 114. Bayer AG Company Detail
    Table 115. Bayer AG Business Overview
    Table 116. Bayer AG Neurodegenerative Disorder Therapeutics Product
    Table 117. Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 118. Bayer AG Recent Development
    Table 119. Eisai Co., Ltd Company Detail
    Table 120. Eisai Co., Ltd Business Overview
    Table 121. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product
    Table 122. Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
    Table 123. Eisai Co., Ltd Recent Development
    Table 124. Research Programs/Design for This Report
    Table 125. Key Data Information from Secondary Sources
    Table 126. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neurodegenerative Disorder Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Neurodegenerative Disorder Therapeutics Market Share by Type: 2023 VS 2030
    Figure 3. Immunomodulators Features
    Figure 4. Interferons Features
    Figure 5. Decarboxylase Inhibitors Features
    Figure 6. Dopamine Agonists Features
    Figure 7. Others Features
    Figure 8. Global Neurodegenerative Disorder Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 9. Global Neurodegenerative Disorder Therapeutics Market Share by Application: 2023 VS 2030
    Figure 10. Multiple Sclerosis Case Studies
    Figure 11. Parkinson'S Disease Case Studies
    Figure 12. Alzheimer'S Disease Case Studies
    Figure 13. Spinal Muscular Atrophy Case Studies
    Figure 14. Huntington Disease Case Studies
    Figure 15. Other Neurodegenerative Disorders Case Studies
    Figure 16. Neurodegenerative Disorder Therapeutics Report Years Considered
    Figure 17. Global Neurodegenerative Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 18. Global Neurodegenerative Disorder Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 19. Global Neurodegenerative Disorder Therapeutics Market Share by Region: 2023 VS 2030
    Figure 20. Global Neurodegenerative Disorder Therapeutics Market Share by Players in 2023
    Figure 21. Global Top Neurodegenerative Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2023)
    Figure 22. The Top 10 and 5 Players Market Share by Neurodegenerative Disorder Therapeutics Revenue in 2023
    Figure 23. North America Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. North America Neurodegenerative Disorder Therapeutics Market Share by Country (2019-2030)
    Figure 25. United States Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Canada Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. Europe Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. Europe Neurodegenerative Disorder Therapeutics Market Share by Country (2019-2030)
    Figure 29. Germany Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. France Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. U.K. Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Italy Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Russia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Nordic Countries Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Share by Region (2019-2030)
    Figure 37. China Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Japan Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. South Korea Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. Southeast Asia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. India Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. Australia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Latin America Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Latin America Neurodegenerative Disorder Therapeutics Market Share by Country (2019-2030)
    Figure 45. Mexico Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Brazil Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Share by Country (2019-2030)
    Figure 49. Turkey Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 50. Saudi Arabia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 51. Biogen, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 52. Pfizer, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 53. Novartis AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 54. Sanofi S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 55. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 56. UCB S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 57. F. Hoffmann- La Roche Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 58. H. Lundbeck Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 59. Merck KGaA Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 60. GlaxoSmithKline PLC Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 61. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 62. Bristol Myers Squibb Company Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 63. Boehringer Ingeiheim International GmbH Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 64. Bayer AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 65. Eisai Co., Ltd Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS